References in periodicals archive ?
A number of technologies are available to record images created during fluoroscopic procedures.
Conventional films can be obtained during fluoroscopic procedures by exposing a screen-film cassette during fluoroscopic viewing.
Radiation safety during fluoroscopic procedures depends on an extensive network of people working together as a team, said Greg Morrison, MA, RT (R), American Society of Radiologic Technologist (ASRT) representative to Image Wisely.
This has placed the radiologic technologist in the position of being the on-site expert, with technologists assuming an additional responsibility for ensuring that the fluoroscopic procedures are performed in a safe manner.
With the addition of mobile, flat detector technology, the AXIOM Sireskop SD provides a single system for all digital radiographic and fluoroscopic procedures.
Military, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc.
In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the VenaCure(TM) Laser Vein Treatment System and the new procedure kit, results of the pending patent litigation with Diomed, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics Inc.
In addition to the matters described above, the ability of the Company to develop its products, first responder market acceptance and sales of RSDL, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc.
In addition to the matters described above, the ability of the Company to develop its products, market acceptance and sales of VoLumen(TM), future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc.
In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the MORPHEUS(TM) CT Injectable PICC, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc.
In addition to the matters described above, the ability of the Company to develop its products, market acceptance and future sales of the Dynamic Flow(TM) chronic hemodialysis catheter, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc.
In addition to the matters described above, the ability of the Company to develop its products, market acceptance of virtual colonoscopy as a new imaging procedure and sales of related products, future Medicare and third-party reimbursement of virtual colonoscopy screening exams, continued growth of the CT imaging market, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, including alternative procedures that continue to replace traditional fluoroscopic procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc.